Opinion statement
In the absence of a culprit epileptogenic lesion, pharmacoresistant seizures should prompt the physician to consider potentially treatable metabolic epilepsies, especially in the presence of developmental delays. Even though the anti-seizure treatment of the epilepsies remains symptomatic and usually tailored to an electroclinical phenotype rather than to an underlying etiology, a thorough metabolic workup might reveal a disease with an etiology-specific treatment. Early diagnosis is essential in the case of treatable metabolic epilepsies allowing timely intervention. Despite the advances in genetic testing, biochemical testing including cerebrospinal fluid studies are still needed to expedite the diagnostic workup and potential therapeutic trials. The diagnostician should have a high index of suspicion despite potential clinical digressions from seminal publications describing the initial cases, as these index patients may represent the most severe form of the condition rather than its most common presenting form. The often gratifying developmental outcome and seizure control with early treatment calls for a prompt diagnostic consideration of treatable metabolic diseases; even though relatively rare or potentially only seemingly so.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Hunt AD Jr, Stokes J Jr, McCrory WW, Stroud HH. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics. 1954;13(2):140–5.
Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med. 2006;12(3):307–9.
•• Darin N, Reid E, Prunetti L, Samuelsson L, Husain RA, Wilson M, et al. Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B 6-dependent epilepsy. Am J Hum Genet. 2016;99(6):1325–37. Identified a new gene that can cause pyridoxine-dependent epilepsy
Ebinger M, Schultze C, Konig S. Demographics and diagnosis of pyridoxine-dependent seizures. J Pediatr. 1999;134(6):795–6.
van Karnebeek CD, Tiebout SA, Niermeijer J, Poll-The BT, Ghani A, Coughlin CR, et al. Pyridoxine-dependent epilepsy: an expanding clinical spectrum. Pediatr Neurol. 2016;59:6–12.
Samanta D. A 15-year-old with seizures: late diagnosis of pyridoxine-dependent epilepsy. Acta Neurol Belg. 2016;116(4):667–9.
Marguet F, Barakizou H, Tebani A, Abily-Donval L, Torre S, Bayoudh F, et al. Pyridoxine-dependent epilepsy: report on three families with neuropathology. Metab Brain Dis. 2016;31(6):1435–43.
Jain-Ghai S, Mishra N, Hahn C, Blaser S, Mercimek-Mahmutoglu S. Fetal onset ventriculomegaly and subependymal cysts in a pyridoxine dependent epilepsy patient. Pediatrics. 2014;133(4):e1092–6.
Gospe SM Jr. Neonatal vitamin-responsive epileptic encephalopathies. Chang Gung Med J. 2010;33(1):1–12.
van Karnebeek CD, Jaggumantri S. Current treatment and management of pyridoxine-dependent epilepsy. Curr Treat Options Neurol. 2015;17(2):1–12.
Al Teneiji A, Bruun TU, Cordeiro D, Patel J, Inbar-Feigenberg M, Weiss S, et al. Phenotype, biochemical features, genotype and treatment outcome of pyridoxine-dependent epilepsy. Metab Brain Dis. 2016:1–9.
Gallagher RC, Van Hove JL, Scharer G, Hyland K, Plecko B, Waters PJ, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol. 2009;65(5):550–6.
Mills PB, Surtees RA, Champion MP, Beesley CE, Dalton N, Scambler PJ, et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum Mol Genet. 2005;14(8):1077–86.
•• Plecko B, Paul K, Mills P, Clayton P, Paschke E, Maier O, et al. Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology. 2014;82(16):1425–33. Challenged the idea that patients with PNPO mutations only respond to PLP treatment
De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med. 1991;325(10):703–9.
• Appavu B, Mangum T, Obeid M. Glucose transporter 1 deficiency: atreatable cause of opsoclonus and epileptic myoclonus. Pediatr Neurol. 2015;53(4):364–6. Found that GLUT1DS manifestations can mimic BMEI
Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain and Development. 2009;31(7):545–52.
•• HaoJ, KellyDI, SuJ, PascualJM. Clinical aspects of glucose transporter type 1 deficiency: information from a global registry. JAMA Neurol2017 Apr 24. Studied the treatment and outcome of 181 GLUT1DS patients from an electronic registry.
Mullen SA, Marini C, Suls A, Mei D, Della Giustina E, Buti D, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Arch Neurol. 2011;68(9):1152–5.
• Larsen J, Johannesen KM, Ek J, Tang S, Marini C, Blichfeldt S, et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia. 2015;56(12):e203–8. Described SLC2A1 mutations in electroclinical phenotypes compatible with childhood absence epilepsy and myoclonic astatic epilepsy
Wang D, Kranz-Eble P, De Vivo DC. Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency syndrome. Hum Mutat. 2000;16(3):224–31.
Gumus H, Bayram AK, Kardas F, Canpolat M, Çağlayan AO, Kumandas S, et al. The effects of ketogenic diet on seizures, cognitive functions, and other neurological disorders in classical phenotype of glucose transporter 1 deficiency syndrome. Neuropediatrics. 2015;46(05):313–20.
Fujii T, Ho Y, Wang D, Darryl C, Miyajima T, Wong H, et al. Three Japanese patients with glucose transporter type 1 deficiency syndrome. Brain Dev. 2007;29(2):92–7.
Klepper J. GLUT1 deficiency syndrome in clinical practice. Epilepsy Res. 2012;100(3):272–7.
WangD, PascualJM, DeVivoD. Glucose transporter type 1 deficiency syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al, editors. GeneReviews(R) Seattle (WA): University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.
Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6. 2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838–49.
Shimomura K, Horster F, de Wet H, Flanagan SE, Ellard S, Hattersley AT, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology. 2007;69(13):1342–9.
Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54(9):2503–13.
Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A. 2004;101(50):17539–44.
Peña-Almazan S. Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation. Diabetes Res Clin Pract. 2015;108(1):e18–20.
Bahi-Buisson N, Roze E, Dionisi C, Escande F, Valayannopoulos V, Feillet F, et al. Neurological aspects of hyperinsulinism–hyperammonaemia syndrome. Dev Med Child Neurology. 2008;50(12):945–9.
Raizen DM, Brooks-Kayal A, Steinkrauss L, Tennekoon GI, Stanley CA, Kelly A. Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations. J Pediatr. 2005;146(3):388–94.
Bahi-Buisson N, Roze E, Dionisi C, Escande F, Valayannopoulos V, Feillet F, et al. Neurological aspects of hyperinsulinism–hyperammonaemia syndrome. Dev Med Child neurol. 2008;50(12):945–9.
Bahi-Buisson N, El Sabbagh S, Soufflet C, Escande F, Boddaert N, Valayannopoulos V, et al. Myoclonic absence epilepsy with photosensitivity and a gain of function mutation in glutamate dehydrogenase. Seizure. 2008;17(7):658–64.
Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998;338(19):1352–7.
Hussain K, Aynsley-Green A, Stanley CA. Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI). Pediatr Endocrinol Rev. 2004;2(Suppl 1):163–7.
Rosenberg EH, Almeida LS, Kleefstra T, Yntema HG, Bahi N, Moraine C, et al. High prevalence of SLC6A8 deficiency in X-linked mental retardation. Am J Hum Genet. 2004;75(1):97–105.
SharerJD, BodamerO, LongoN, TortorelliS, WamelinkMM, YoungS. Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics. Genet Med 2017.
Dunbar M, Jaggumantri S, Sargent M, Stockler-Ipsiroglu S, van Karnebeek CD. Treatment of X-linked creatine transporter (SLC6A8) deficiency: systematic review of the literature and three new cases. Mol Genet Metab. 2014;112(4):259–74.
Dhar S, Scaglia F, Li F, Smith L, Barshop B, Eng C, et al. Expanded clinical and molecular spectrum of guanidinoacetate methyltransferase (GAMT) deficiency. Mol Genet Metab. 2009;96(1):38–43.
Mikati AG, Gheida IA, Shamseddine A, Mikati MA, Karam PE. Epileptic and electroencephalographic manifestations of guanidinoacetate-methyltransferase deficiency. Epileptic Disord. 2013;15(4):407–16.
Stockler S, Holzbach U, Hanefeld F, Marquardt I, Helms G, Requart M, et al. Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res. 1994;36(3):409–13.
Schulze A. Creatine deficiency syndromes. Mol Cell Biochem. 2003;244(1):143–50.
BlauN, DuranM, GibsonKM, Dionisi-ViciC, BlaskovicsME. Physician’s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. : Springer;2014.
El-Hattab AW, Shaheen R, Hertecant J, Galadari HI, Albaqawi BS, Nabil A, et al. On the phenotypic spectrum of serine biosynthesis defects. J Inherit Metab Dis. 2016;39(3):373–81.
De Koning T, Jaeken J, Pineda M, Van Maldergem L, Van der Knaap M. Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics. 2000;31(06):287–92.
Benke PJ, Hidalgo RJ, Braffman BH, Jans J, Gassen KLIV, Sunbul R, et al. Infantile serine biosynthesis defect due to phosphoglycerate dehydrogenase deficiency: variability in phenotype and treatment response, novel mutations, and diagnostic challenges. J Child Neurol. 2017;32(6):543–9.
Tabatabaie L, Klomp L, Rubio-Gozalbo M, Spaapen L, Haagen A, Dorland L, et al. Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency. J Inherit Metab Dis. 2011;34(1):181–4.
Hart CE, Race V, Achouri Y, Wiame E, Sharrard M, Olpin SE, et al. Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am J Hum Genet. 2007;80(5):931–7.
De Koning T, Klomp L, Van Oppen A, Beemer F, Dorland L, Van Den Berg I, et al. Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet. 2004;364(9452):2221–2.
De Koning T, Duran M, Maldergem LV, Pineda M, Dorland L, Gooskens R, et al. Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids. J Inherit Metab Dis. 2002;25(2):119–25.
Thöny B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat. 2006;27(9):870–8.
Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis. 2012;35(6):963–73.
Jäggi L, Zurflüh MR, Schuler A, Ponzone A, Porta F, Fiori L, et al. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab. 2008;93(3):295–305.
Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012;71(4):520–30.
•• Carducci C, Santagata S, Friedman J, Pasquini E, Carducci C, Tolve M, et al. Urine sepiapterin excretion as a new diagnostic marker for sepiapterin reductase deficiency. Mol Genet Metab. 2015;115(4):157–60. Described a new test for sepiapterin deficiency, which, unlike the other tetrahydrobiopterin deficiencies, is not detected in the newborn phenylketonuria screening
AlSubhi S, AlShahwan S, AlMuhaizae M, AlZaidan H, Tabarki B. Sepiapterin reductase deficiency: report of 5 new cases. Eur J Paediatr Neurol. 2017;21(3):583–6.
Biasucci G, Valsasina R, Giovannini M, Brioschi M, Saleri L, Riva E. Neuroradiological improvement after one year of therapy in a case of DHPR deficiency. Chem Biol Pteridines. 1989:438–44.
Ramaekers V, Sequeira JM, Quadros EV. Clinical recognition and aspects of the cerebral folate deficiency syndromes. Clin Chem Lab Med. 2013;51(3):497–511.
Cario H, Bode H, Debatin KM, Opladen T, Schwarz K. Congenital null mutations of the FOLR1 gene: a progressive neurologic disease and its treatment. Neurology. 2009;73(24):2127–9.
Ramaekers VT, Rothenberg SP, Sequeira JM, Opladen T, Blau N, Quadros EV, et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med. 2005;352(19):1985–91.
Steinfeld R, Grapp M, Kraetzner R, Dreha-Kulaczewski S, Helms G, Dechent P, et al. Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet. 2009;85(3):354–63.
Pineda M, Ormazabal A, López-Gallardo E, Nascimento A, Solano A, Herrero MD, et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann Neurol. 2006;59(2):394–8.
Wolf B. The neurology of biotinidase deficiency. Mol Genet Metab. 2011;104(1–2):27–34.
Wolf B. Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without and vision loss. Mol Genet Metab. 2015;116(3):113–8.
Yilmaz S, Serin M, Canda E, Eraslan C, Tekin H, Ucar SK, et al. A treatable cause of myelopathy and vision loss mimicking neuromyelitis optica spectrum disorder: late-onset biotinidase deficiency. Metab Brain Dis. 2017;9
Dulac O, Plecko B, Gataullina S, Wolf NI. Occasional seizures, epilepsy, and inborn errors of metabolism. Lancet Neurol. 2014;13(7):727–39.
Hoover-Fong JE, Shah S, Van Hove JL, Applegarth D, Toone J, Hamosh A. Natural history of nonketotic hyperglycinemia in 65 patients. Neurology. 2004;63(10):1847–53.
Hennermann JB, Berger J, Grieben U, Scharer G, Van Hove JL. Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Dis. 2012;35(2):253–61.
Dinopoulos A, Matsubara Y, Kure S. Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab. 2005;86(1–2):61–9.
Brunel-Guitton C, Casey B, Coulter-Mackie M, Vallance H, Hewes D, Stockler-Ipsiroglu S, et al. Late-onset nonketotic hyperglycinemia caused by a novel homozygous missense mutation in the GLDC gene. Mol Genet Metab. 2011;103(2):193–6.
Coughlin CR II, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pombo P, et al. The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT. Genet Med. 2016;19(1):104–11.
Van Hove JL, Vande Kerckhove K, Hennermann JB, Mahieu V, Declercq P, Mertens S, et al. Benzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis. 2005;28(5):651–63.
Obeid M, Wyllie E, Rahi AC, Mikati MA. Approach to pediatric epilepsy surgery: state of the art, Part I: General principles and presurgical workup. Eur J Paediatr Neurol. 2009;13(2):102–14.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Pediatric Neurology
Rights and permissions
About this article
Cite this article
Assi, L., Saklawi, Y., Karam, P.E. et al. Treatable Genetic Metabolic Epilepsies. Curr Treat Options Neurol 19, 30 (2017). https://doi.org/10.1007/s11940-017-0467-0
Published:
DOI: https://doi.org/10.1007/s11940-017-0467-0